Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
A buy-back less than 1 year after an IPO? Its almost as if personal assets need to stay high for some reason... The IPO was given, apparently investment in R&D is lower than other competitors, the funds raised, some institutions and individuals made wealthier, there's extradition talk, and now a buy back. I don't like where this is heading, call me the ghost of Christmas future all you want.
by which I mean CRST.
Lol. Is it because it is a housebuilder that's based in SURREY where all the brokers and traders live?
Why the rise today? Inflation high, interest rates going up, where the cheer in this sector today?
this is news from January 2021.
If your dividends are above the annual allowance £2000 and therefore subject to tax, then it looks to me like you fill this in on your self assessment tax return, and HMRC will adjust the resulting tax / rebate accordingly.
I sold out earlier this year with 200%, back in now that the legal stuff is settled and a divi policy has been stated. There are so much good divis on offer at the moment if you can stomach to volatility.
IMO: This is related to the Tesco cyber attack not peel hunt. Basically, if you are a hacker in a unscrupulous country, you could make a fortune by opening a short on IT security firms such as.., then cyber attack a UK company or a client, then close the short. I'd expect volatility and there's no one way ride, as previous poster has said, this looks like a bull trap. There might be customer numbers and revenue growing, but how good is the product actually and how much volatility should we expect on the basis of clients unsuccessfully repelling cyber attacks.
Added today also, balance sheet + strong dividends and room for acquisitions. I bet the raising interest will not do as much to curb inflation as BoE hopes because the cat is out the bag and too much raising of interest rates will kill the UK economy.
Good news. Can't see what all the fuss is about charging for revenue at the moment. They are going through the process of acquiring data from customers because it has value more than the sum of its parts when together and analysed, in much the same way tech firms collect your data in order to exploit it. People need to chill about revenue and licensing now, if you think the data will be valuable then I don't see any issue, and charging more in future will happen. The important things is to collect as much of the Digi-glassware data as possible, which may make it a bit of a loss leader. No one like share dilution, and the prospect of this is driving the price down, that's all IMO.
There are plenty of loss making companies that make a tidy sum for holders. I can't really figure out why companies losing 10-50 million PA over the last 10 years can have a market cap of 100s £ mill., whilst DMTR gets a pasting for losses of £1mill and increasing R&D slightly. I think they are doing the right thing by developing there product, but I agree seeing directors take home plenty for running a loss-making business these days is not on, and they should be doing better.
Bought some today. UK has been doing QE and been doing stuff to stimulate the housing market for the last decade and it still hasn't run its course. When it does, what then? Will people vote in a government that slows house price inflation or causes people to be in negative equity - ? No, the train is runaway and it has still some way to go before being bust. Until then, I'll that dividend yield with plenty of growth potential. There's plenty of liquidity available for Persimmon to borrow, buy land, build and then sell at a smooth 26% margin.
What is keeping this company afloat, it has been making a loss for the last decade? Beats me.
It's like tumbleweed on this sharechat. Pretty sure the West are going to be heading into an arms race again. Got exposure to North America, Australasia, UK and the supply chains therein on recurring revenues, so seems like a safe buy.
You need leverage somewhere. Yes revenue look small but growing end of last FY but as has been said, we don't know what the contracts are, only the timescales and partners, so I'd presume if the tech is worth more to the big players then they will pay more or lose to competition. I would speculate that they would/should be talking to well established scientific hardware manufacturers also to see if the embedded technology and AI analysis of data can be developed outside of Pharma and into other high-end manufacturing.
Depends how many people and how many shares are prepared to sell at sub 2p IMO. I agree its not the done thing. At the moment the selling looks driven by RG doing what RG does, clearly not enough buyers. The question is why - products on sale in UK and US, multiple blue chip customers that almost cover the all the big pharma player, recurring annual revenue.... and we have a market cap of £15 mill. Bottom line is we need an institutional investor with deeper pockets.
Looks like an AIM treeshake. Don't set stop losses and just hold fast for a top up when you think it is time. If there is another fundraiser, its looking a more tempting prospect than it did at the last share issue, therefore I can't seeing the price being lower than 2 p let alone 1.5p.